Skip to content

Veralox Therapeutics

Site Navigation

  • Team
    • Management Team
    • Advisory Board
    • Board of Directors
  • Technology
  • Investors
  • News
  • Contact Us

Veralox Therapeutics Sitemap

Pages

  • Contact Us
  • Home
  • Investors
  • News
  • Privacy Policy
  • Teams
    • Advisory Board
    • Board of Directors
    • Management Team
  • Technology

Posts by category

  • Category: Company News and Events
    • Veralox Therapeutics Appoints Lisa Beck as Chief Business Officer
    • Veralox Therapeutics Appoints Michael Hanna As Chief Medical Officer
    • Veralox Therapeutics Announces Closing Of $16.6 Million Series A Financing And Announces New Board Members
    • Veralox Therapeutics Announces FDA Orphan Drug Designation for VLX-1005
    • Veralox Therapeutics Announces IND Submission for VLX-1005 to Treat Heparin-Inducted Thrombocytopenia
    • Veralox Therapeutics Appoints Life Sciences Industry Veteran Alex Martin as Chairman of the Board of Directors
    • Veralox Therapeutics Raises $5.4 Million in Seed Funding Co-Led by JDRF T1D Fund and Sanofi Ventures
    • Biotech Startups On the Rise in Frederick, Maryland
    • Frederick Innovative Technology Center, Inc. – Success Story
    • Meet Our Clients: Jeff Strovel, CEO of VERALOX Therapeutics

Start building your business roadmap.

Contact Us to Get Started

Veralox Therapeutics

Footer Navigation

  • Management Team
  • Technology
  • News
  • Contact Us

Follow Us

Copyright 2019 – 2022 Veralox Therapeutics  |  Privacy Policy | Website design by Wood Street, Inc.